Navigation Links
AMDL, Inc. Completes Revision of Performance & Equity Incentive Compensation Plan

TUSTIN, Calif., Jan. 8 /PRNewswire-FirstCall/ -- AMDL, Inc. (NYSE Alternext US: ADL), a vertically integrated pharmaceutical company with operations in China and the U.S., announced today it has revised its 2009 Performance and Equity Incentive Compensation Plan for senior management and employees.

Under the terms of the Plan, AMDL has transitioned from a "discretionary cash and options-based bonus plan" to a performance-based, stock and cash incentive plan. Incentives are based on successfully achieving financial targets established by AMDL's Board of Directors.

Plan highlights include:

  • Performance based incentive awards
  • Board-determined quarterly income performance targets
  • Limited cash bonus awards
  • Reaffirmation of AMDL's commitment to not issue discretionary incentive awards

According to Mr. Michael Boswell, independent board member and Chairman of AMDL's Compensation and Audit Committees, "We have made a deliberate decision to establish a more structured compensation plan that directly links our executive and employee compensation to Company performance. In establishing this new plan, we are creating stronger alignment between the interests of our management team, employees, and investors. We feel the modifications made support AMDL's long-term success."

Under AMDL's 2009 Performance and Equity Incentive Compensation Plan, all stock granted to senior executives and employees as incentive compensation will be scheduled to vest only if the Company's meets its strategic goals and specific financial performance targets. AMDL's Board of Directors and Compensation Committee have reviewed and approved the performance targets and Plan outlined above. Detailed information on this revised Plan can be found in AMDL's Form 8-K filed with the Securities and Exchange Commission.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    (Tel :) 206. 310.5323

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Research Report
2. AMDL, Inc. Selected as #1 Small-Cap Stock Pick for 2009
3. Ambulatory Services of America, Inc. Completes Purchase of Majority Interest in Rosa of Georgia, LLC
4. Kentucky Medical Services Foundation Completes Successful Charge Capture Technology Conversion
5. Escalon(R) Medical Corp. Completes Bolt-On Acquisition, Enhances Market Position in France and Expands Product Offering
6. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
7. Blue Cross and Blue Shield of Florida Completes Acquisition of Florida Health Care Plans
8. Hard To Treat Diseases (HTDS) Completes E Europe Merger
9. New Zealand Waynes New Resources Development Co., Ltd. Completes Reverse Merger to Go Public in the U.S.
10. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
11. Smart Financial Credit Union Completes Key FCU Merger
Post Your Comments:
(Date:11/25/2015)... Omaha, Neb. (PRWEB) , ... November 25, 2015 ... ... nurse staffing companies, has been recognized once again for its stellar workplace culture ... Places to Work.” , Medical Solutions’ Cincinnati office was named a ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and ... Pan African Centres of Excellence, and public R&D institutions, civil societies and other ... of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
(Date:11/25/2015)... ... 2015 , ... On November 25, 2015, officials of Narconon Arrowhead , ... release of a new cutting edge recovery program that has been 50 years in ... and alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative ...
(Date:11/25/2015)... ... ... On November 23rd 2015 Cozy Products, a division of Bird-X ... Products explains what this means for business moving forward. , The Tri Lite heater ... model: to sell personal heaters that reduce energy consumption, are economical and keep people ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  The American Academy ... Gynecologists (ACOG), and the March of Dimes cheered ... Protecting Our Infants Act of 2015 (S.799), ... of newborns born exposed to drugs, such as ... bill,s introduction, all three organizations have worked together ...
(Date:11/25/2015)... , Nov. 25, 2015 On ... first federal bellwether trial against Wright Medical Technology, ... to their Conserve metal-on-metal hip implant device, awarded ... Following a two week trial and three days ... metal-on-metal hip device was defectively designed and unreasonably ...
(Date:11/25/2015)... Israel , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused ... treatment of various clinical conditions, today announced the closing ... American Depository Shares ( ADSs ), each representing 20 ... up to 3,158,900 ADSs. The ADSs and warrants were ...
Breaking Medicine Technology: